Earnings Call Bluebird Bio Reports Robust Q2 2024 Results Optimistic Outlook

Bluebird Bio Reports Second Quarter 2024 Results and Highlights Operational Progress

Q2 2024 Results Call Transcript

Opening Remarks

Welcome to the bluebird bio second quarter 2024 results conference call. My name is Courtney O’Leary, Director of Corporate Communications.

Today’s call will include remarks from Nick Leschly, our CEO; Andrew Obenshain, our CFO; and Dr. David Davidson, our Chief Medical Officer.

Operational Progress

In the second quarter of 2024, bluebird bio reported strong progress in its commercial and clinical operations.

The company continues to ramp up production of its two approved gene therapies, ZYNTEGLO and SKYSONA.

Enrollment in clinical trials for its pipeline candidates is ongoing, with the Phase 2/3 HGB-206 study fully enrolled.

bluebird bio is also exploring strategic partnerships to expand its global reach and commercial capabilities.

Financial Performance

bluebird bio reported financial results that were largely in line with analyst expectations.

• Total revenue for the quarter was $124.4 million, an increase of 12% year-over-year.
• Product revenue was $113.4 million, driven by sales of ZYNTEGLO and SKYSONA.
• Net loss for the quarter was $125.2 million, or $1.03 per share.

Outlook

bluebird bio provided an update on its guidance for the full year 2024.

• The company expects to generate total revenue in the range of $500 million to $550 million.
• Product revenue is expected to be in the range of $450 million to $500 million.
• Net loss for the year is expected to be in the range of $450 million to $500 million.

Conference Call Details

To listen to the full conference call, please visit the bluebird bio website at https://ir.bluebirdbio.com/events-and-presentations/default.aspx

About bluebird bio

bluebird bio is a clinical-stage gene therapy company. The company's mission is to develop and commercialize transformative gene therapies for severe genetic diseases.